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Rnd3 as a Novel Target to Ameliorate Microvascular Leakage
Jerome W. Breslin, PhD; Dayle A. Daines, PhD; Travis M. Doggett, PhD; Kristine H. Kurtz, PhD; Flavia M. Souza-Smith, PhD;
Xun E. Zhang, MD; Mack H. Wu, MD; Sarah Y. Yuan, MD, PhD
Background-—Microvascular leakage of plasma proteins is a hallmark of inflammation that leads to tissue dysfunction. There are
no current therapeutic strategies to reduce microvascular permeability. The purpose of this study was to identify the role of Rnd3,
an atypical Rho family GTPase, in the control of endothelial barrier integrity. The potential therapeutic benefit of Rnd3 protein
delivery to ameliorate microvascular leakage was also investigated.
Methods and Results-—Using immunofluorescence microscopy, Rnd3 was observed primarily in cytoplasmic areas around the
nuclei of human umbilical vein endothelial cells. Permeability to fluorescein isothiocyanate–albumin and transendothelial electrical
resistance of human umbilical vein endothelial cell monolayers served as indices of barrier function, and RhoA, Rac1, and Cdc42
activities were determined using G-LISA assays. Overexpression of Rnd3 significantly reduced the magnitude of thrombin-induced
barrier dysfunction, and abolished thrombin-induced Rac1 inactivation. Depleting Rnd3 expression with siRNA significantly
extended the time course of thrombin-induced barrier dysfunction and Rac1 inactivation. Time-lapse microscopy of human
umbilical vein endothelial cells expressing GFP-actin showed that co-expression of mCherry-Rnd3 attenuated thrombin-induced
reductions in local lamellipodia that accompany endothelial barrier dysfunction. Lastly, a novel Rnd3 protein delivery method
reduced microvascular leakage in a rat model of hemorrhagic shock and resuscitation, assessed by both intravital microscopic
observation of extravasation of fluorescein isothiocyanate–albumin from the mesenteric microcirculation, and direct determination
of solute permeability in intact isolated venules.
Conclusions-—The data suggest that Rnd3 can shift the balance of RhoA and Rac1 signaling in endothelial cells. In addition, our
findings suggest the therapeutic, anti-inflammatory potential of delivering Rnd3 to promote endothelial barrier recovery during
inflammatory challenge. ( J Am Heart Assoc. 2016;5:e003336 doi: 10.1161/JAHA.116.003336)
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E levated microvascular permeability is a significantproblem that accompanies uncontrolled inflammation,
contributing to tissue injury and dysfunction. Much work over
the past several decades has improved our understanding of
the endothelium, the main permselective barrier at leakage
sites, in inflammation. However, a successful strategy to
ameliorate microvascular hyperpermeability in a clinical
setting remains elusive.1
Previous work has highlighted the active role of endothelial
cells in regulating microvascular permeability with attention
paid to their subcellular structures, including adherens
junctions, focal adhesions, and the cytoskeleton.2 Activation
of endothelial cells by inflammatory cells or soluble inflam-
matory mediators triggers several signaling cascades that
lead to cytoskeletal rearrangement and disruption of inter-
cellular adherens junctions, enhancing paracellular flux of
fluids and solutes.3–6 Several experiments have shown that
the hyperpermeability response to inflammatory stimuli is
often transient,3,6–8 although the precise mechanisms
involved in its termination are not well defined.
We previously reported that the small GTPase RhoA and its
downstream effector Rho-associated kinase (ROCK) mediate
neutrophil-induced hyperpermeability.5,6 Others have also
reported that RhoA/ROCK can increase hydraulic conductivity
in single-perfused microvessels.9,10 ROCK can phosphorylate
the myosin light chain phosphatase targeting subunit (MYPT-
1), leading to inactivation of myosin light chain phosphatase,
and accumulation of myosin light chain phosphorylated on
Thr-18 and Ser-19 by myosin light chain kinase.11,12 Several
reports have suggested that inflammatory mediators promote
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excess phosphorylated myosin light chain, which may interact
with actin to open intercellular junctions, either through
contractile or retractile mechanisms.3,13–18 Despite these
advances, a caveat to using inhibition of RhoA/ROCK to
reduce microvascular hyperpermeability is the fact that this
pathway is also important for maintaining endothelial barrier
function under noninflammatory conditions,17,19,20 as RhoA
activation near cell borders promotes endothelial barrier
integrity.21 Thus, inhibition of RhoA may lead to different
outcomes depending on specific subcellular sites of action.
Additionally, other Rho family small GTPases, particularly
Rac1 and Cdc42, have been shown to be important for
maintaining microvascular barrier function and may work by
either stabilizing cortical actin or promoting local membrane
protrusions to promote junctional stability.17,22–24 In addition,
the expression levels and activities of various Rho family
GTPases are also known to influence one other.25 Thus,
altering the balance of activities among different Rho family
GTPases may also represent a way to improve microvascular
barrier function.
One group of Rho family GTPases that has not received
much attention is the Rnd subfamily. Unlike most GTPases,
which cycle between GTP- and GDP-bound states and thus act
like molecular switches in signaling pathways, Rnd proteins
are deficient in GTPase activity, and are probably regulated in
large part at the transcriptional level.26 Rnd3 is the most
commonly expressed member of this subfamily and is
ubiquitously expressed.27–29 In addition to transcriptional
regulation, Rnd3 is also phosphorylated by ROCK1 and PKCa,
promoting its stabilization and translocation between the
membrane and cytosolic fractions.30,31 Rnd3 overexpression
can inhibit the RhoA-ROCK signaling pathway by suppressing
RhoA activity through a p190RhoGAP-dependent pathway, as
well as by binding to and inhibiting downstream ROCK I
signaling.32,33 This Rnd3-mediated inhibition of RhoA has also
been shown to enhance tight junction barrier function in
mammary epithelial cells.34,35 In endothelial cells, Rnd3
overexpression was reported to initially reduce actin stress
fibers, but after 24 hours result in elevated actin stress fiber
formation and changes in junctional structure due to upreg-
ulation of RhoB.36 However, it has not been previously
reported whether modulation of Rnd3 expression causes
changes in endothelial barrier function.
In the current study, we investigated the potential role of
Rnd3 in the control of endothelial permeability. We first
confirmed the expression of Rnd3 in microvessels and
vascular endothelial cells. Next, using thrombin-induced
endothelial barrier dysfunction, which we previously reported
involves activation of RhoA and inactivation of Rac1, we then
tested the hypothesis that Rnd3 can promote resolution of
thrombin-induced endothelial barrier dysfunction through its
influence on Rho family GTPase activities and cytoskeletal
mechanisms. For these studies we used Rnd3 overexpression
and depletion in cultured endothelial cell monolayers. We then
tested the ability of delivering Rnd3 protein into the micro-
circulation as a strategy to reduce microvascular hyperper-
meability caused by injury, using an established rat
hemorrhagic shock and resuscitation (HSR) model.
Methods
Cell Culture
Human umbilical vein endothelial cells (HUVEC) were obtained
from Lonza (Basel, Switzerland) and grown in Clonetics
endothelial growth medium-2 (EGM-2, Lonza). Prior to exper-
iments, the medium was changed to endothelial basal
medium as indicated.
Generation of Rnd3 Fusion Proteins
Open Biosystems clone #MHS1010-58455 (RND3 cDNA) was
purified from DH10B Escherichia coli and selection was
confirmed by HindIII restriction digest and agarose gel
electrophoresis. The gene was amplified using Phusion high-
fidelity DNA polymerase (New England Biolabs, Ipswich, MA)
for subcloning into pCMV-MAT-FLAG-1 (Sigma, St. Louis, MO)
using the oligonucleotides: 50-AAGGCAGATATCATGAAGGAGA-
GAAGAGCCAGC-30 (RND3 EcoRV forward primer) and 50-
AATGGGTACCTCACATCACAGTGCAGC-30 (RND3 TGA KpnI
reverse primer). The vector and amplicon were EcoRV/KpnI
digested, purified, and ligated overnight with T4 DNA ligase.
The ligation mix was used to transform competent
Escherichia coli DH5a, and clones were selected on LB plates
with 100 lg/mL ampicillin. This yielded human MAT-FLAG-
RND3 (in frame), controlled by a CMV promoter. The Rnd3
cDNA was also subcloned into the N-terminal mCherry
destination vector using the Gateway system (Invitrogen,
Grand Island, NY). All constructs were verified by sequencing,
and the plasmids were purified for transfection with the
EndoFree MaxiPrep kit (Qiagen, Valencia, CA).
Plasmid Transfection
Cells were transfected with plasmids encoding MAT-FLAG-
Rnd3, mCherry-Rnd3, GFP-Actin, GFP, or with no vector (mock
transfection) using the NucleofectorTM II System (Lonza)
according to the manufacturer’s instructions. Briefly, HUVEC
grown to 80% to 90% confluence in EGM-2 were trypsinized,
and washed with PBS. The number of cells was counted, the
suspension was centrifuged at 100g for 10 minutes, and the
pellet was resuspended in HUVEC Nucleofector solution
(Lonza) at 59106 cells/mL. Plasmid DNA (2 lg) was added
to 100 lL of the cell suspension, and the mixture was
DOI: 10.1161/JAHA.116.003336 Journal of the American Heart Association 2





















transferred into a cuvette for nucleofection. Immediately after
nucleofection, 500 lL of prewarmed EGM-2MV was added to
the cuvette, and after a 15-minute incubation at 37°C, the
cells were seeded into either 35-mm culture dishes, electrode
arrays, or Transwell plates for study. Medium was changed 4
to 6 hours posttransfection. Cells were used for study at 1 to
2 days posttransfection. Expression of fluorescent proteins
was confirmed using a microscope with appropriate epifluo-
rescent illumination. Expression of MAT-FLAG-Rnd3 was
confirmed by Western blotting and immunofluorescence
labeling.
Rnd3 and RhoA siRNA
Specific siRNAs for inhibiting Rnd3 (siGENOME SMARTpool M-
007794-02) or RhoA (M-003860-03) expression were
obtained from Dharmacon (Chicago, IL). Cells were trans-
fected siRNA (15–150 pmol) with the Nucleofector II system
as described above. Nontargeting siRNA (siCONTROL) served
as control. Cells were used 2 days posttransfection. Pools of
siRNA were chosen over individual sequences in order to
maximize loss of target function while minimizing off-target
effects.37,38
Western Blotting
HUVEC were washed with ice-cold PBS and protein lysates
were obtained by lysis in ice-cold RIPA buffer (Upstate)
containing 1X HALT protease inhibitor cocktail (Pierce, Rock-
ford, IL). Protein concentrations were determined with the
Bradford assay, and equal amounts of protein were loaded for
SDS-PAGE. Proteins were transferred to nitrocellulose for
Western blotting with the following primary antibodies over-
night at 4°C: mouse anti-RhoE/Rnd3, clone 4 (Merck Millipore
05-723, 1:1000 dilution, Billerica, MA), rabbit anti-Rho (Merck
Millipore 06-770, 1:1000), or rabbit anti-tubulin (Santa Cruz
Biotechnology, H-235/sc-9104, Santa Cruz, CA). Anti-rabbit
and anti-mouse secondary (HRP conjugated) antibodies were
from Jackson Immunoresearch (West Grove, PA). To identify
the FLAG probe, we used mouse anti-FLAG MS-peroxidase
conjugate (Sigma A8592, 1:500) at room temperature for
1 hour. Bands were visualized by chemiluminescence.
Electrical Cell-Substrate Impedance Sensing
Transendothelial electrical resistance (TER) was determined
as an index of endothelial barrier function as previously
described6,20 with an electrical cell-substrate impedance
sensing 1600R system (Applied Biophysics, Troy, NY). Briefly,
cells were cultured (105 cells/cm2) on 8W1E small gold
electrode arrays (Applied Biophysics). Medium served as the
electrolyte and barrier function was dynamically measured by
determining the impedance of a cell-covered electrode. A 1-V,
4000-Hz AC signal was supplied through a 1-MΩ resistor to
approximate a constant-current source. The in-phase voltage
(proportional to resistance) and the out-of-phase voltage
(proportional to capacitive resistance) were measured.
Endothelial monolayers with baseline resistance values below
5000 Ω were excluded from the study.
Endothelial Monolayer Permeability Assay
HUVEC were grown 4 to 5 days on gelatin-coated Costar
Transwell membranes (VWR, Houston, TX) as previously
described.4,5 Endothelial basal medium containing fluorescein
isothiocyanate–albumin was added to the upper (luminal)
chamber. Thrombin (1 U/mL) or vehicle control (PBS) was
also added to the upper chamber. Samples were collected
from both the upper and lower (abluminal) chambers at
various time points for fluorometry analysis. Albumin concen-
trations were determined using a standard curve, and the
apparent permeability coefficient for albumin (Ps
albumin) was
calculated as: Ps
albumin=[A]/t91/A9V/[L]; where [A] is the
abluminal albumin concentration, t is time in seconds, A is the
area of the membrane in cm2, V is the volume of the abluminal
chamber, and [L] is the luminal albumin concentration.
RhoA, Rac1, and Cdc42G-LISA Activation Assays
GTP-bound RhoA, Rac1, and Cdc42 were used as indicators of
RhoA, Rac1, and Cdc42 activation, respectively. These were
determined as previously described17 using the RhoA and
Rac1G-LISATM activation assay luminescence kits and
Cdc42G-LISATM activation assay colorimetric kit (Cytoskele-
ton, Inc., Denver, CO) according to the manufacturer’s
instructions. HUVEC were transfected with plasmid or siRNA
(or appropriate controls) and cultured for 2 days on 60-mm
plates. Cells were serum starved overnight prior to the start of
the experiment. Thrombin (1 U/mL) was added for 5, 30, 60,
or 120 minutes. The cells were lysed and 1 set of lysate
aliquots was snap frozen until the start of the assay. Another
set of aliquots was used to determine protein concentrations.
Protein concentrations were then equilibrated in the first set
of aliquots and then for each sample, lysate (25 lL) and
binding buffer (25 lL) were added to wells in a RhoA-GTP,
Rac1-GTP, or Cdc42-GTP affinity plate for 30 minutes. Bound
RhoA-GTP, Rac1-GTP, or Cdc42-GTP was detected with
specific primary antibodies, and HRP-conjugated secondary
antibody. For the RhoA and Rac1 assays, chemiluminescence
agent was added to the wells and luminescence was
measured in a SpectraMax2 plate reader (Molecular Devices,
Sunnyvale, CA). For the Cdc42 assay, a colorimetric reagent
was added and the plates were read at 490 nm in a Tecan
Infinite 200 plate reader (Tecan Group, Ltd., M€annedorf,
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Switzerland). This technique was chosen to quantify RhoA-,
Rac1-, and Cdc42-GTP rather than the Western blot method
because (1) this technique produces quantitative data
whereas Western blots are only semiquantitative, and (2)
the ELISA can be completed in 3 hours versus over 2 days
for the more traditional pulldown assay and Western blot,
enabling us to perform a more detailed study of the time
course of RhoA, Rac1, and Cdc42 activation.
Time Lapse Imaging of Endothelial Cells
Experiments were performed as previously described17,18,39
using a Nikon Eclipse TE2000U inverted microscope system
(Nikon Instruments, Melville, NY). Briefly, HUVEC expressing
GFP-actin, with or without co-expression of mCherryRnd3, were
perfused with warm (37°C) albumin–physiological salt solution
(APSS; NaCl, 120 mmol/L; KCl, 4.7 mmol/L; CaCl22H2O,
2 mmol/L; MgSO47H2O, 1.2 mmol/L; NaH2PO4, 1.2 mmol/
L; Na pyruvate, 2 mmol/L; glucose, 5 mmol/L; EDTA,
0.02 mmol/L; MOPS, 3 mmol/L; purified BSA 1 g/100 mL;
pH 7.4). Fluorescent images (S492 and S572 excitation filters)
were acquired every 15 seconds. Time-lapse image sets were
then analyzed by counting the number of local lamellipodia that
appear over time, using ImageJ.
Cell-Permeable (CP)-Rnd3 Mixture Preparation
Purified Rnd3 protein was obtained from Origene (Rockville,
MD) and mixed with TransITLT-1 polyamine transfection
reagent40,41 in APSS. The mixture was applied directly to
the mesentery (topically) or in the isolated microvessel bath at
final concentrations of 2 lg protein/mL and 10 lL TransIT-
LT1/mL. As a control, a mixture with only 10 lL TransIT-LT1/
mL in APSS was used. We have previously used this method
to successfully deliver purified proteins into isolated venules
and lymphatic vessels, producing functional changes.6,40–43
Animal Procedures
All animal procedures were approved by the University of
South Florida and LSUHSC-NO Institutional Animal Care and
Use committees and were performed in strict accordance
with the U.S. Animal Welfare Act, U.S. Public Health Service
Policy on the Humane Care and Use of Laboratory Animals,
and the NIH Guide for the Care and Use of Laboratory Animals.
All surgery was performed after the rats were anesthetized,
and all efforts were made to minimize pain. Male Sprague
Dawley rats were obtained from Charles River Laboratories
(Wilmington, MA) and provided a standard diet (Purina Rat
Chow, Ralston Purina, St. Louis, MO) and water ad libitum.
The rats were housed in a 12 hours light/12 hours dark cycle
for a 1-week acclimation period prior to surgery.
Collection of Rat Mesentery for
Immunofluorescence Labeling
The rats (200–250 g) were anesthetized with ketamine/
xylazine (40/5 mg/kg, i.m.). After a rat was anesthetized, a
midline laparotomy was performed. A section of small
intestine (ileum) and mesentery was excised and placed into
cold PBS. Each rat was then immediately euthanized by an
overdose of sodium pentobarbital (120 mg/kg, i.v.) followed
by cervical dislocation. The luminal contents of the intestine
were removed by compression in order to avoid enzyme
digestion of the tissue in subsequent steps. The mesentery
was dissected away from the intestine, washed several times
with cold PBS, and mounted with pins on a silicone surface for
fixation and immunolabeling.
Immunofluorescence Microscopy
HUVEC grown on gelatin-coated coverslips or mesentery
specimens were fixed with freshly prepared 4%
paraformaldehyde and permeabilized with 0.2% Triton X-
100. Specimens were then blocked in 2% donkey serum
(Sigma). For labeling of recombinant MAT-FLAG-Rnd3, the
fixed cells were incubated with a monoclonal anti-FLAG M2
antibody (Sigma #F1804, 1:1000 dilution) for 2 hours at
37°C. Native Rnd3 in HUVEC was labeled overnight at 4°C
with mouse anti-RhoE/Rnd3, clone 4 (Merck-Millipore #05-
723, 1:100). Native Rnd3 and VE-cadherin in rat mesentery
were labeled overnight at 4°C with rabbit anti-Rnd3
(ProteinTech #12534-1-AP, 1:500) and goat anti-VE-cadherin
(Santa Cruz #sc-6458), respectively. Secondary antibodies
(Jackson Immunoresearch), namely, Cy2-conjugated donkey
anti-mouse IgG (#715-225-150, 1:100), Cy2-conjugated
donkey anti-goat IgG (#705-225-003, 1:100), or Texas
Red–conjugated donkey anti-rabbit IgG (#711-075-152,
1:100), were applied for 1.5 hours at room temperature.
The mesenteric samples were transferred to slides, and
whole mounted with Vectashield (Vector Laboratories,
Burlingame, CA). Coverslips with HUVEC were mounted in
a similar fashion. Fluorescent microscopy was performed
with either a Nikon Eclipse TE2000-U inverted fluorescent
microscope equipped with a Photometrics CoolSnap HQ
digital camera and Metamorph 6.1 software for acquisition
and analysis (Nikon Instruments, Lewisville, TX), or a Zeiss
Axiovert 200M fluorescent microscope equipped with an
Axiocam camera and Axiovision software (Carl Zeiss, Thorn-
wood, NY).
Conscious Rat Model of HSR
A previously established model of hemorrhagic shock in
conscious, unrestrained rats44,45 was used to produce
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microvascular hyperpermeability in the gut. At least 48 hours
prior to the day of the experiment, rats were anesthetized with
ketamine and xylazine (90 and 9 mg/kg, respectively), and
sterile catheters were implanted in the left common carotid
artery and right external jugular vein. The catheters were
flushed with 0.9% sterile sodium chloride USP (Baxter,
Deerfield, IL), thermally sealed, and routed subcutaneously
with a trocar to the dorsal nape of the neck. The catheters
were then secured to the closed incision with a suture, coiled,
and wrapped in masking tape to prevent damage. The carotid
catheters were used to monitor blood pressure and for
removal of blood. The jugular catheters were used for
administration of fluorescent tracers for intravital microscopy.
After surgery, the rats were allowed 2 to 3 days of recovery
prior to experiments.
On the days of the experiments, the rats were placed into
smaller cages positioned over a heating pad. The arterial
catheter was attached to a pressure transducer connected to
a PowerLab 4/35 Quad Bridge amplifier and computer
running LabChart Pro software (ADInstruments, Colorado
Springs, CO). Baseline arterial pressure was measured for at
least 1 hour. Next, blood was withdrawn from conscious,
unrestrained rats via the arterial catheter to produce a fixed-
pressure hemorrhage to 40 mm Hg mean arterial pressure.
After this was maintained for 60 minutes, fluid resuscitation
was provided using Lactate-Ringer’s solution USP, delivered
through the intravenous catheter initially as a bolus equal to
40% of the total blood volume removed to produce the
hemorrhage, plus an additional 29 the total blood volume
removed as an intravenous infusion over 1 hour. Blood
pressure measurements continued during all parts of the
protocol except during the time when blood was removed
from the arterial catheter. Time-matched, sham control rats
did not have blood removed during the 1-hour hemorrhage
period.
Assessment of Extravasation by Intravital
Microscopy
Immediately following the hemorrhage/resuscitation proto-
col, rats were anesthetized and prepared for intravital
microscopy as previously described.46 Briefly, the ventral
fur was shaved and skin cleaned, and a midline laparotomy
was performed in order to exteriorize the small intestine and
associated mesentery over an optical stage. The mesentery
was superfused with APSS at 37°C. Body temperature was
monitored using a rectal thermometer connected to a
thermostat-controlled heating pad to keep the rat warm.
Blood pressure was monitored via the arterial catheter.
Fluorescein isothiocyanate–albumin, dissolved in Lactate
Ringer’s solution, which served as a tracer for extravasation
of plasma proteins, was administered via the jugular vein
catheter as a bolus (0.1 mg/kg) followed by continuous
infusion (0.15 mg/kg per minute) to generate a steady-state
blood concentration. After a 30-minute period to allow for
stabilization, epifluorescent images of the mesenteric
microcirculation were obtained at 10-minute intervals,
initially just prior to addition of the CP-Rnd3 mixture and
for an additional 1 hour. Extravasation was quantified by
measuring the integrated optical intensity of the interstitial
spaces adjacent to postcapillary venules as previously
described.46–48 Arteriole diameters were also measured
within the same images to test for potential changes in
blood flow to the tissue.1
Isolated, Perfused Venule Permeability Model
Isolation of mesenteric venules was performed as previously
described.17 Briefly, after the hemorrhagic shock/resuscita-
tion protocol, rats were anesthetized, a midline laparotomy
was performed, and the small intestine and associated
mesentery were excised and pinned into a cold dissection
chamber. The rats were euthanized by an overdose of
ketamine/xylazine. A mesenteric venule (40–80-lm diameter,
0.5–1.0-mm length) was carefully dissected, excised, and
mounted onto 2 resistance-matched glass micropipettes,
preserving the natural length of the vessel, in a custom
isolated vessel chamber containing warm (37°C) APSS. The 2
pipettes were connected to inflow and outflow reservoirs
containing APSS. A third, smaller micropipette, inserted into
the inflow pipette, served as a source for Alexa Fluor-488
albumin in APSS, which served as a tracer. Venular perme-
ability was determined by measuring transvascular flux and
transmural concentration of the Alexa Fluor-488 tracer.
Ps
albumin was calculated as Ps
albumin=(1/DIf)(dIf/dt)0(r/2),
where DIf is the initial step increase in fluorescent intensity
when switching to the APSS containing Alexa Fluor 488-
albumin, (dIf/dt)0 is the initial rate of the more gradual
increase in fluorescence intensity due to flux of the tracer
across the vessel wall into the surrounding bath, and r is the
radius of the venule.49 For all experiments the net perfusion
pressure was held at 10 cm H2O and the flow velocity was
7 mm/s.
Data Analysis
Data are presented as meansSE. For some experiments,
data were normalized to baseline prior to calculating the
means and SE. For time course experiments involving
repeated measures, intergroup differences were tested with
repeated-measures ANOVA followed by Bonferroni t-tests. For
other studies, differences were evaluated using 1-way ANOVA
followed by Tukey’s multiple comparisons test. Significance
was accepted at P<0.05.
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Rnd3 Expression in Endothelial Cells
Rnd3 was detected by immunofluorescence microscopy in
both the rat mesenteric microcirculation (Figure 1A) and
within individual endothelial cells (Figure 1B and 1C). The
subcellular localization of Rnd3 was typically concentrated
within a perinuclear region resembling tubule-like structures
surrounding the nucleus (Figure 1B). Confocal images with
additional immunolabeling of TGN46 showed that some of the
Rnd3 is localized within the trans-Golgi network (Figure 1C).
Inhibition of Rnd3 Expression Extends Thrombin-
Induced Endothelial Barrier Dysfunction
We first aimed to determine the extent to which reducing
endogenous Rnd3 expression may affect endothelial barrier
function. Transfection of HUVEC with Rnd3 siRNA reduced
Rnd3 protein in a concentration-dependent manner, without
affecting RhoA or b-tubulin, which served as loading controls
(Figure 2A). In HUVEC monolayers transfected with Rnd3
siRNA or siCONTROL nontargeting RNA, there were no
differences in mean baseline TER (Table 1). There was also
no difference in the initial reduction in TER caused by the
barrier-disrupting agent thrombin (Figure 2B). However, there
was a significant difference in the return to baseline between
the 2 groups. Rnd3 siRNA treatment caused a prolonged
decrease in TER that did not recover as quickly as with
siCONTROL RNA-treated cells (Figure 2B). This same trend
was also observed when we determined changes in the
apparent permeability to albumin (Ps
albumin) for these 2
groups. There was no difference in the initial increase in
Ps
albumin caused by thrombin; however, Ps
albumin remained
elevated much longer in the Rnd3 siRNA-treated cells than in




Figure 1. Rnd3 in the microcirculation and in cultured endothelial cells. A, Widefield images of a rat
mesenteric window labeled with anti-Rnd3 (top) and anti-VE-cadherin antibodies (bottom), showing a
relatively high degree of Rnd3 labeling in microvessels. B, Widefield image of HUVEC labeled with anti-Rnd3
antibodies, revealing strong patches of Rnd3 labeling adjacent to the nuclei (large arrows), and tubule-like
labeling reaching into the cytoplasm (small arrows). C, Single confocal slice images of Rnd3 labeling (left),
with counter-labeling for the trans-Golgi network with TGN46 (middle), in HUVEC. The overlay image shows
that a portion of the intense areas of Rnd3 labeling near the nuclei are within the trans-Golgi network.
Images are representative of at least 3 separate labeling experiments. These labeling patterns were not
observed in control experiments with no primary antibody (not shown). HUVEC indicates human umbilical
vein endothelial cells.
DOI: 10.1161/JAHA.116.003336 Journal of the American Heart Association 6





















Rnd3 Overexpression Inhibits Thrombin-Induced
Barrier Dysfunction of Cultured Endothelial Cells
We also performed gain-of-function experiments by overex-
pressing Rnd3 inHUVEC. Successful transfection ofMAT-FLAG-
Rnd3 was confirmed using Western blotting (Figure 3A). The
degree of expression within individual cells was variable, with
some cells expressing very high amounts of MAT-FLAG-Rnd3,
and others expressing very little. Dense localization of this
ectopic Rnd3 could often be found in perinuclear areas but also
occurred near the cell periphery in cells with very high
expression (Figure 3B). Transfection of HUVEC with MAT-
FLAG-Rnd3 had little effect on baseline TER or Pa, compared to a
mock transfection with no vector (Tables 1 and 2). However,
thrombin-induced barrier dysfunction was significantly inhib-
ited in HUVEC expressing MAT-FLAG-Rnd3, compared to mock
transfection (Figure 3C). A similar trendwas observed using the
monolayer permeability model (Figure 3D). These data further
support the concept that Rnd3 promotes enhanced barrier
function when endothelial cells are challenged with an inflam-
matory stimulus.
Influence of Rnd3 on Thrombin-Induced RhoA,
Rac1, and Cdc42 Activation
To better understand the mechanism of the observed changes
in thrombin-induced barrier dysfunction with altered Rnd3
expression, we investigated how Rnd3 overexpression and
depletion affect thrombin-induced changes in RhoA, Rac1, and
Cdc42 activities (Figure 4). To our surprise, overexpression
with MAT-FLAG-Rnd3 had little impact on thrombin-induced
RhoA activation (Figure 4A). However, MAT-FLAG-Rnd3
expression did inhibit thrombin-induced inactivation of Rac1
at 5 minutes (Figure 4B), and had no impact on Cdc42
activation (Figure 4C). Depletion of Rnd3 with siRNA, how-
ever, caused a slightly more sustained activation of RhoA
(Figure 4D) and inactivation of Rac1 (Figure 4E) by thrombin,
with little impact on Cdc42 (Figure 4F).
Rnd3 Overexpression Prevents Thrombin-Induced
Cell Retraction
We next investigated the impact of Rnd3 on thrombin-induced
changes in the actin cytoskeleton that contribute to the
changes in barrier function. For these studies, we utilized
HUVEC expressing GFP-actin, in order to evaluate dynamic
Figure 2. Impact of specific Rnd3 depletion on
thrombin-induced endothelial barrier dysfunction.
A, Concentration-dependent impact of Rnd3 siRNA
on Rnd3 expression in HUVEC vs siCONTROL
nontargeting RNA (Ctrl). RhoA and b-tubulin served
as loading controls. Blots are representative of 3
experiments. B, Specific Rnd3 depletion with siRNA
prolongs thrombin-induced decreases in HUVEC
monolayer TER. C, Rnd3 depletion also prolongs
thrombin-induced increases in Ps
albumin. §P<0.05,
§§P<0.01 vs baseline. *P<0.05 vs siCONTROL,
same time point. HUVEC indicates human umbilical
vein endothelial cells; TER, transendothelial electri-
cal resistance.
Table 1. Baseline TER of Untransfected HUVEC Monolayers
Versus Those Transfected With Rnd3 siRNA, siCONTROL RNA,
MAT-FLAG-Rnd3, or no Vector/siRNA (Mock)
Group Mean TERSE (Ω) N
No transfection 6890118 6
siCONTROL 6853369 8
Rnd3 siRNA 6976384 6
Mock 6947298 9
MAT-FLAG-RND3 7348290 11
HUVEC indicates human umbilical vein endothelial cells; TER, transendothelial electrical
resistance.
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changes in cell shape and the number of actin stress fibers
present. Cells expressing either GFP-actin alone, or co-
expressing mCherry-Rnd3 were used for study. We first
evaluated protrusive activity at cell borders (Figure 5A). In
HUVEC expressing only GFP-actin, thrombin caused a rapid
and significant decrease in the frequency of local lamellipodia
protrusions, in a similar fashion as previously reported.17 In
cells co-expressing mCherry-Rnd3, the reduction in the
protrusion frequency of local lamellipodia caused by thrombin
was less pronounced (Figure 5A). Thrombin also causes
increased actin stress fiber formation in endothelial cells. In
the current study, the number of actin fibers present in
HUVEC expressing only GFP-actin increased significantly after
thrombin was added (Figure 5B). However, this was not the
case in cells co-expressing mCherry-Rnd3, due in part
because these cells already had a slightly elevated number
of actin fibers during baseline. Lastly, the ventral surface
area covered by HUVEC expressing only GFP-actin signifi-
cantly decreased after the addition of thrombin, but in cells




Figure 3. Rnd3 overexpression attenuates thrombin-induced endothelial barrier dysfunction. A, Western
blot showing overexpression of MAT-FLAG-Rnd3 in HUVEC. B, Immunofluorescence image showing very
high expression of MAT-FLAG-Rnd3 (green) throughout the cytoplasm in 2 transfected cells. Nuclei are
labeled blue. The large arrows show areas of high expression in the perinuclear area, similar to those seen
with endogenous Rnd3. The small arrows show accumulation at the cell borders and cell–cell contacts. C,
Rnd3 overexpression in HUVEC attenuates the thrombin-induced drop in TER and increase in Ps
albumin (D).
*P<0.05, **P<0.01 between groups at the same time point. §P<0.05, §§P<0.01 vs baseline. HUVEC
indicates human umbilical vein endothelial cells; IB, immunoblot; TER, transendothelial electrical resistance.
Table 2. Baseline Ps
albumin of Untransfected HUVEC
Monolayers Versus Those Transfected With Rnd3 siRNA,
siCONTROL RNA, MAT-FLAG-Rnd3, or no Vector/siRNA
(Mock)
Group Mean Ps
albuminSE (9106 cm/s) N
No transfection 8.11.4 6
siCONTROL 6.70.6 4
Rnd3 siRNA 7.31.0 4
Mock 9.71.6 8
MAT-FLAG-RND3 8.21.1 8
HUVEC indicates human umbilical vein endothelial cells.
DOI: 10.1161/JAHA.116.003336 Journal of the American Heart Association 8





















(Figure 5C). Collectively, these results show that overexpres-
sion of Rnd3 significantly reduces the changes in the actin
cytoskeleton elicited by thrombin that facilitate cellular
retraction.
Transfection of Rnd3 Protein Ameliorates
Microvascular Hyperpermeability
We next determined to what extent these findings in cells
apply to the intact microcirculation. Using a method we
previously developed and refined to directly deliver proteins
into cells and microvessels,3,6,40,42,50,51 we tested the poten-
tial therapeutic utility of Rnd3 to reduce microvascular
hyperpermeability caused by HSR.52 The mesenteric venules
isolated from rats following this injury had a significantly
elevated mean Ps
albumin compared to time-matched sham
controls (Figure 6A). When the CP-Rnd3 mixture was added to
the isolated vessel perfusion bath of venules from rats that
had undergone HSR, the mean Ps
albumin gradually decreased,
and after 30 minutes of treatment was significantly lower
than that observed for HSR without CP-Rnd3 treatment
(Figure 6A). With this promising result, we assessed the
extent to which local CP-Rnd3 treatment may improve
microvascular leakage in vivo. Following HSR, microvascular
leakage was evident, with fluorescein isothiocyanate–albumin
steadily extravasated from the mesenteric microcirculation
over time. However, when CP-Rnd3 was topically applied onto
the mesentery, this extravasation was dramatically decreased
(Figure 6B). Combined, these data suggest that transfection
of Rnd3 protein into microvessels is an effective short-term
method to reduce microvascular permeability following an
ischemic injury in the gut.
Discussion
In this study, we identified that an atypical Rho family small
GTPase, Rnd3, is expressed in endothelial cells. Using a
combination of cell culture, ex vivo, and in vivo approaches,
we have identified evidence supporting that Rnd3 has barrier-
protective properties under certain conditions, such as
following acute inflammatory challenge. The involvement of
Rnd3 in the control of endothelial barrier function adds to a
Figure 4. Impact of Rnd3 overexpression or depletion on RhoA, Rac1, and Cdc42 activation by thrombin. A, RhoA-GTP activation in mock-
transfected or MAT-FLAG-Rnd3-transfected HUVEC monolayers during baseline conditions and 5, 30, 60, and 120 minutes following the
addition of 1 U/mL thrombin. B and C, Rac1 and Cdc42 activation, respectively, under the same conditions. D, RhoA activation in HUVEC
treated with Rnd3 siRNA or siCONTROL nontargeting RNA under baseline conditions and after treatment with 1 U/mL thrombin for 5, 30, 60, or
120 minutes. E and F, Activation of Rac1 and Cdc42 under the same conditions. *P<0.05 vs baseline. †P<0.05 vs. MAT-FLAG-Rnd3, same time
point. §P<0.05 between groups, same time point. The numbers in parentheses at each time point indicate the number of replicates for the mock
and MAT-FLAG-Rnd3 groups, respectively, in (A through C) and for the siCONTROL and Rnd3 siRNA groups, respectively, in (D through F).
HUVEC indicates human umbilical vein endothelial cells.
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growing list of recently described functions ascribed to Rnd
family proteins, including Ca2+ homeostasis in the heart,53
regulation of Notch1 signaling,54 control of cell cycle
progression,55–57 development of the central nervous sys-
tem,58–60 control of cell motility and metastatic potential of
certain cancers,29,61–64 and a potential role in cardioprotec-
tion against heart failure.65 In addition, we provide novel
evidence that delivery of Rnd3 protein can serve as a potential
therapeutic tool to ameliorate microvascular hyperpermeabil-
ity caused by tissue injury.
Rnd3 was initially chosen for study because of its known
role as an inhibitor of RhoA/ROCK signaling. RhoA and ROCK
have an interesting dual role in the control of endothelial
barrier function. Several reports have indicated that
activation of RhoA/ROCK is important for inflammatory
mediator–induced endothelial barrier dysfunction.5,6,22,23,66–71
However, RhoA and ROCK activation are also involved with
S1P-induced endothelial barrier enhancement.17,19 An elegant
study utilizing a fluorescence resonance energy transfer
biosensor expressed in endothelial cells to report RhoA
activity provided evidence that differential localization of RhoA
activation is key for its function to promote or disrupt
endothelial barrier function. Activation of RhoA in central
regions of endothelial cells, which is elicited by thrombin, is
responsible for disruption of the endothelial barrier, while
RhoA activation at the cell periphery promotes annealing of
disrupted junctions.21 In the current study, we observed that
endogenous Rnd3 was localized primarily in perinuclear
regions of the cytoplasm (Figure 1). Based on this finding,
we would expect that any inhibitory action by endogenous
Rnd3 on RhoA/ROCK signaling would likely be localized to the
central regions of the cells. This notion is supported by our
findings that siRNA-mediated knockdown of Rnd3 expression
caused longer time courses of thrombin-induced barrier
dysfunction in HUVEC monolayers in association with
extended periods of RhoA activation. It is worth noting that
the general concept of signals localized in the perinuclear or
centralized areas of the cytoplasm rapidly leading to elevated
permeability of the endothelium has previously been shown in
studies of endothelial nitric oxide synthase activation local-
ized to the cytosol or Golgi apparatus,72–74 leading to the
downstream S-nitrosylation of junction-associated proteins.75
Focal adhesion kinase–induced activation of p190RhoGAP
has been described as part of the feedback mechanism that
limits thrombin-induced activation of RhoA in endothelial
cells.76 Knowing this, and that Rnd3 was shown to activate
p190RhoGAP in COS7 and 3T3 cells,32 we originally predicted
that overexpression of Rnd3 in HUVEC would suppress
thrombin-induced RhoA activation. However, our results
indicated this was not the case (Figure 4) and therefore we
did not pursue this or the interaction between Rnd3 and
p190RhoGAP further. As alternatives, we investigated Rac1
and Cdc42, 2 other key Rho family small GTPases that
contribute to the control of endothelial barrier func-
tion.22,24,77–79 Thrombin caused a rapid, significant decrease
in Rac1-GTP in agreement with several previous
reports.17,78,80,81 However, thrombin did not activate Cdc42
in HUVEC, in contrast to one previous report that described a
Figure 5. Rnd3 overexpression limits thrombin-induced actin cytoskeletal changes and endothelial cell retraction. HUVEC expressing GFP-
actin alone (Control) or in combination with mCherry-Rnd3 were used for these experiments. A, The protrusion frequency of local lamellipodia is
shown for baseline (BL) and at 10-minute intervals after the addition of 1 U/mL thrombin. *P<0.05 and **P<0.01 vs baseline, same treatment
group. B, In the same groups of cells, actin fibers were counted at baseline and after addition of thrombin. The mean peak number of fibers after
the addition of thrombin is shown. †P<0.05 vs baseline for the nontransfected control group. C, Changes in the ventral surface area covered by
each cell were determined at baseline, and 30 and 60 minutes after the addition of thrombin. Data normalized to the mean at baseline for each
group are shown. §P<0.05 mCherry-Rnd3 vs control, same time point. N=6 cells in each group. HUVEC indicates human umbilical vein
endothelial cells.
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delayed activation of Cdc42 in immortalized human dermal
microvascular endothelial cells.71 It is worth noting that the
same immortalized cell line also does not display Rac1
inactivation in response to thrombin.82 When we modulated
Rnd3 expression, thrombin-induced inactivation of Rac1 was
affected. Overexpression of Rnd3 abolished thrombin-induced
Rac1 inactivation, while siRNA knockdown of Rnd3 caused
prolonged inhibition of Rac1 by thrombin (Figure 4). To our
knowledge, this is the first demonstration that modulating
expression of Rnd3 can have an impact on Rac1 activity.
Inhibition of Rac1 has previously been shown to increase
permeability of venules.17 There is evidence that Rac1 can
stabilize cortical actin to promote junctional stability in
endothelial cells.22,23 In addition, coordinated, cyclic activity
of Rac1 and RhoA are known to control the protrusion and
withdrawal of cell protrusions.83 Recently, we reported that
treatment of endothelial cells with either thrombin or a
selective inhibitor of Rac1 can decrease the protrusion
frequency of small, local lamellipodia in conjunction with
disruption of the endothelial barrier.17 These protrusions, also
termed junctional-associated intermittent lamellipodia by
other investigators,84,85 are also disrupted by histamine and
appear to control rapid changes in permeability by altering the
overlap of adjacent endothelial cells.18 In the current study,
cells overexpressing Rnd3 had a less pronounced thrombin-
induced reduction in the frequency of local lamellipodia
(Figure 5). This finding supports the notion that the ability of
Rnd3 overexpression to decrease thrombin-induced endothe-
lial barrier dysfunction is in part attributable to an inhibition of
those signals that disrupt normal protrusive activity that
produces overlap of endothelial cells at intercellular junctions.
Previous reports have indicated that Rnd3 overexpression
can profoundly affect actin stress fibers. Overexpression of
Rnd3 causes the loss of actin stress fibers in cultured MDCK
cells, astrocytes, and Swiss 3T3 fibroblasts.28,29,56,86,87 In
HUVEC, however, Rnd3 expression has been reported to
increase actin stress fiber formation, which was attributed to
increased transcription and activity of RhoB.36 We have
observed similar findings in nonconfluent, fixed HUVEC
expressing MAT-FLAG-Rnd3 (data not shown). In confluent
HUVEC co-expressing mCherry-Rnd3 with GFP-actin, the actin
stress fibers appeared more numerous than in cells express-
Figure 6. Rnd3 protein delivery ameliorates hemorrhagic shock and resuscitation (HSR)–induced
microvascular hyperpermeability. A, The apparent permeability of isolated, perfused mesenteric
venules to albumin (Ps
albumin) was determined. Venules isolated from rats that underwent a 60-
minute fixed pressure hemorrhage (40 mm Hg) followed by 60-minute resuscitation with lactated
Ringer’s solution (HSR) had a significantly higher Ps
albumin than time-matched sham rats that did not
undergo hemorrhage (*P<0.05 vs sham, same time point). Addition of the CP-Rnd3 mixture to the
vessel perfusion bath (2 lg/mL of Rnd3 protein and 10 lL/mL of TransIT-LT1) reduced Ps
albumin in
isolated venules from rats that underwent HSR (§P<0.05 vs HSR, same time point). B, Extravasation
of intravenously infused FITC-albumin from the mesenteric microcirculation was assessed by
intravital microscopy after rats underwent HSR. The intensity in extravascular spaces adjacent to
postcapillary venules increased over time; however, this was prevented when the CP-Rnd3 mixture
was applied to the suffusion bathing the mesentery (2 lg/mL of Rnd3 protein and 10 lL/mL of
TransIT-LT1). *P<0.05 HSR vs HSR+CP-Rnd3, same time point). CP indicates cell permeable; FITC,
fluorescein isothiocyanate.
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ing GFP-actin alone, although according to strict statistical
analysis these differences were not significant. However, the
significant increase in actin stress fibers normally observed in
response to thrombin was blunted in cells co-expressing
mCherry-Rnd3 (Figure 5). This was somewhat surprising
because in another experiment, Rnd3 overexpression did
not prevent thrombin-induced RhoA activation (Figure 4). This
might indicate that the maximal number of actin stress fibers
that could be generated was already reached in the cells
overexpressing Rnd3, prior to thrombin treatment. In addition,
the actin stress fibers observed in cells overexpressing Rnd3
might be qualitatively different from those that arise in
response to thrombin activation, possibly more mature and
with stronger focal adhesions, because Rnd3 overexpression
also prevented thrombin-induced retraction of cells. Focal
adhesions found at the tips of ventral stress fibers help
maintain endothelial cell spreading, and their disruption leads
to retraction and has been shown to increase permeability of
single-perfused venules.88–91 Additional work will be needed
to elucidate further molecular details at the subcellular level.
To translate the findings from cells to pathophysiologically
relevant conditions, we investigated the potential therapeutic
use of CP-Rnd3 to reduce microvascular permeability in a
more clinically relevant model. HSR is known to produce
systemic inflammation, including elevated microvascular
leakage in the gut.2,52 In our current study, HSR produced a
profound increase in both the permeability of isolated venules
and in the mesenteric microcirculation. Application of CP-
Rnd3 reversed this effect of HSR. This finding is significant
because of the current lack of drugs or biological agents that
can reduce microvascular permeability during injury and
inflammation. It is important to note that in the current study
we have limited our investigation to relatively acute increases
in permeability. It is currently unclear how effective this or
similar strategies will be when the endothelium is in a more
advanced pathophysiologic state, such as with sepsis.
In summary, the current study presents a novel role for
Rnd3 in endothelial barrier function. The mechanism involves
modulation of the balance between Rac1 and RhoA activation,
and alterations in the actin cytoskeleton that are important
for determining cell shape and the integrity of intercellular
junctions. Importantly, the data show that delivery of Rnd3
protein to intact microvessels or whole tissues can reduce
microvascular leakage after injury. Additional studies on this
and related potential therapies to reduce inflammation
represent an important area of investigation that requires
more attention.
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